Jeff Yass: Acadia Pharmaceuticals ACAD Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 12.7 M | Compra |
629,800
+577,700
| +1,109% | +USD 15.5 M | ﹤0.01% | 3023 |
|
|
2026
Q2 | USD 1.32 M | Compra |
52,100
+3,900
| +8% | +USD 85.8 k | ﹤0.01% | 7489 |
|
|
2026
Q1 | USD 1.07 M | Compra |
48,200
+1,600
| +3% | +USD 38.2 k | ﹤0.01% | 7707 |
|
|
2025
Q4 | USD 1.24 M | Venta |
46,600
-313,600
| -87% | -USD 7.49 M | ﹤0.01% | 6670 |
|
|
2025
Q3 | USD 7.69 M | Compra |
360,200
+307,400
| +582% | +USD 7.27 M | ﹤0.01% | 3400 |
|
|
2025
Q2 | USD 1.14 M | Venta |
52,800
-24,900
| -32% | -USD 463 k | ﹤0.01% | 7109 |
|
|
2025
Q1 | USD 1.29 M | Venta |
77,700
-62,700
| -45% | -USD 1.14 M | ﹤0.01% | 6612 |
|
|
2024
Q4 | USD 2.58 M | Compra |
140,400
+52,300
| +59% | +USD 844 k | ﹤0.01% | 4754 |
|
|
2024
Q3 | USD 1.35 M | Compra |
88,100
+37,400
| +74% | +USD 624 k | ﹤0.01% | 6143 |
|
|
2024
Q2 | USD 824 k | Venta |
50,700
-122,800
| -71% | -USD 1.98 M | ﹤0.01% | 7053 |
|
|
2024
Q1 | USD 3.21 M | Compra |
173,500
+85,400
| +97% | +USD 2.12 M | ﹤0.01% | 4389 |
|
|
2023
Q4 | USD 2.76 M | Venta |
88,100
-532,300
| -86% | -USD 12.7 M | ﹤0.01% | 4724 |
|
|
2023
Q3 | USD 12.9 M | Compra |
620,400
+564,100
| +1,002% | +USD 15.3 M | ﹤0.01% | 2237 |
|
|
2023
Q2 | USD 1.35 M | Compra |
56,300
+13,900
| +33% | +USD 309 k | ﹤0.01% | 5999 |
|
|
2023
Q1 | USD 798 k | Compra |
42,400
+19,900
| +88% | +USD 379 k | ﹤0.01% | 7419 |
|
|
2022
Q4 | USD 358 k | Venta |
22,500
-90,100
| -80% | -USD 1.41 M | ﹤0.01% | 8670 |
|
|
2022
Q3 | USD 1.84 M | Venta |
112,600
-176,800
| -61% | -USD 2.86 M | ﹤0.01% | 5083 |
|
|
2022
Q2 | USD 4.08 M | Compra |
289,400
+37,200
| +15% | +USD 694 k | ﹤0.01% | 3520 |
|
|
2022
Q1 | USD 6.11 M | Compra |
252,200
+76,300
| +43% | +USD 1.85 M | ﹤0.01% | 3310 |
|
|
2021
Q4 | USD 4.11 M | Compra |
175,900
+7,300
| +4% | +USD 147 k | ﹤0.01% | 4089 |
|
|
2021
Q3 | USD 2.8 M | Venta |
168,600
-130,300
| -44% | -USD 2.51 M | ﹤0.01% | 5096 |
|
|
2021
Q2 | USD 7.29 M | Venta |
298,900
-456,300
| -60% | -USD 10.3 M | ﹤0.01% | 3374 |
|
|
2021
Q1 | USD 19.5 M | Compra |
755,200
+592,800
| +365% | +USD 26.1 M | ﹤0.01% | 1905 |
|
|
2020
Q4 | USD 8.68 M | Venta |
162,400
-63,900
| -28% | -USD 3.17 M | ﹤0.01% | 2666 |
|
|
2020
Q3 | USD 9.34 M | Compra |
226,300
+50,600
| +29% | +USD 2.19 M | ﹤0.01% | 2264 |
|
|
2020
Q2 | USD 8.52 M | Compra |
175,700
+77,600
| +79% | +USD 3.73 M | ﹤0.01% | 2337 |
|
|
2020
Q1 | USD 4.14 M | Venta |
98,100
-454,200
| -82% | -USD 18.7 M | ﹤0.01% | 2820 |
|
|
2019
Q4 | USD 23.6 M | Venta |
552,300
-6,700
| -1% | -USD 291 k | 0.01% | 1272 |
|
|
2019
Q3 | USD 20.1 M | Compra |
559,000
+13,200
| +2% | +USD 400 k | 0.01% | 1323 |
|
|
2019
Q2 | USD 14.6 M | Compra |
545,800
+23,300
| +4% | +USD 595 k | 0.01% | 1536 |
|
|
2019
Q1 | USD 14 M | Venta |
522,500
-203,000
| -28% | -USD 4.74 M | 0.01% | 1465 |
|
|
2018
Q4 | USD 11.7 M | Venta |
725,500
-179,600
| -20% | -USD 3.49 M | ﹤0.01% | 1463 |
|
|
2018
Q3 | USD 18.8 M | Compra |
905,100
+359,200
| +66% | +USD 5.65 M | 0.01% | 1372 |
|
|
2018
Q2 | USD 8.34 M | Venta |
545,900
-359,500
| -40% | -USD 6.41 M | ﹤0.01% | 2124 |
|
|
2018
Q1 | USD 20.3 M | Compra |
905,400
+407,900
| +82% | +USD 11.3 M | 0.01% | 1198 |
|
|
2017
Q4 | USD 15 M | Venta |
497,500
-18,400
| -4% | -USD 588 k | 0.01% | 1477 |
|
|
2017
Q3 | USD 19.4 M | Venta |
515,900
-88,400
| -15% | -USD 2.88 M | 0.01% | 1249 |
|
|
2017
Q2 | USD 16.9 M | Venta |
604,300
-338,900
| -36% | -USD 10.1 M | 0.01% | 1280 |
|
|
2017
Q1 | USD 32.4 M | Venta |
943,200
-324,900
| -26% | -USD 11.5 M | 0.02% | 776 |
|
|
2016
Q4 | USD 36.6 M | Compra |
1,268,100
+400,600
| +46% | +USD 10.6 M | 0.02% | 696 |
|
|
2016
Q3 | USD 27.6 M | Sin cambios |
867,500
| – | – | 0.01% | 811 |
|
|
2016
Q2 | USD 28.2 M | Venta |
867,500
-471,200
| -35% | -USD 15.8 M | 0.02% | 778 |
|
|
2016
Q1 | USD 37.4 M | Compra |
1,338,700
+373,200
| +39% | +USD 8.14 M | 0.02% | 650 |
|
|
2015
Q4 | USD 34.4 M | Compra |
965,500
+106,500
| +12% | +USD 3.75 M | 0.02% | 793 |
|
|
2015
Q3 | USD 28.4 M | Compra |
859,000
+291,400
| +51% | +USD 12.1 M | 0.01% | 946 |
|
|
2015
Q2 | USD 23.8 M | Venta |
567,600
-180,800
| -24% | -USD 7 M | 0.01% | 1158 |
|
|
2015
Q1 | USD 24.4 M | Compra |
748,400
+197,200
| +36% | +USD 6.78 M | 0.01% | 1090 |
|
|
2014
Q4 | USD 17.5 M | Compra |
551,200
+60,800
| +12% | +USD 1.72 M | 0.01% | 1459 |
|
|
2014
Q3 | USD 12.1 M | Venta |
490,400
-48,300
| -9% | -USD 1.13 M | ﹤0.01% | 1901 |
|
|
2014
Q2 | USD 12.2 M | Venta |
538,700
-19,100
| -3% | -USD 399 k | 0.01% | 1903 |
|
|
2014
Q1 | USD 13.6 M | Compra |
557,800
+289,500
| +108% | +USD 7.32 M | 0.01% | 1663 |
|
|
2013
Q4 | USD 6.7 M | Venta |
268,300
-34,200
| -11% | -USD 807 k | ﹤0.01% | 2533 |
|
|
2013
Q3 | USD 8.31 M | Venta |
302,500
-107,600
| -26% | -USD 2.25 M | ﹤0.01% | 2097 |
|
|
2013
Q2 | USD 7.44 M | Compra |
+410,100
| Nuevas | +USD 5.65 M | ﹤0.01% | 2147 |
|
Otros fondos que tienen ACAD en su portafolio
BBA
Posición de Jeff Yass en ACAD: resumen de T3 2026
Jeff Yass aumentó su participación en Acadia Pharmaceuticals (ACAD) en 119% durante T3 2026, al comprar aproximadamente USD 1.91 M y elevar la posición a 130,792 acciones con un valor de USD 2.64 M. La posición representa ﹤0.01% del portafolio y ocupa el puesto #5686.
Jeff Yass reportó por primera vez una posición en ACAD en T2 2013 y desde entonces la ha mantenido en 52 trimestres. La posición alcanzó su máximo de USD 32.3 M en T4 2014. Al cierre de T3 2026, 351 fondos que sigue Wall St. Rank mantienen una posición en ACAD.
- Al cierre de T3 2026, Jeff Yass tenía 130,792 acciones de Acadia Pharmaceuticals con un valor de USD 2.64 M.
- Jeff Yass compró 71,056 acciones de Acadia Pharmaceuticals en T3 2026, por un monto estimado de USD 1.91 M.
- Acadia Pharmaceuticals representó el ﹤0.01% del portafolio de Jeff Yass en T3 2026 y fue su posición número 5686.
- Jeff Yass reportó por primera vez una posición en Acadia Pharmaceuticals en T2 2013 y desde entonces la ha mantenido en 52 trimestres.
- La posición de Jeff Yass en Acadia Pharmaceuticals alcanzó su máximo de USD 32.3 M en T4 2014.
- Al cierre de T3 2026, 351 fondos que sigue Wall St. Rank tenían Acadia Pharmaceuticals en su portafolio.
Según el informe 13F de Susquehanna International Group correspondiente a T3 2026, presentado el 16 nov 2026.